Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial

Market Focus07-15 20:59

On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.

On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. The study demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.

This data further expands Keytruda's indication footprint in precision oncology. Recent positive developments including FDA approval of Keytruda plus Padcev for muscle-invasive bladder cancer and Keytruda plus Trodelvy for first-line triple-negative breast cancer, combined with multiple investment banks raising price targets — JPMorgan to $140, BMO to $142, Wells Fargo to $150, and Scotiabank to $155 — have collectively bolstered market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192281608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192281608","market":"us","top_or_hot":-1,"title":"Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial","media":"Market Focus","content":"<html><head></head><body><p style=\"text-align: left;\">On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.</p><p style=\"text-align: left;\">On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. The study demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.</p><p style=\"text-align: left;\">This data further expands Keytruda&#39;s indication footprint in precision oncology. Recent positive developments including FDA approval of Keytruda plus Padcev for muscle-invasive bladder cancer and Keytruda plus Trodelvy for first-line triple-negative breast cancer, combined with multiple investment banks raising price targets — JPMorgan to $140, BMO to $142, Wells Fargo to $150, and Scotiabank to $155 — have collectively bolstered market sentiment.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 20:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.</p><p style=\"text-align: left;\">On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. The study demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.</p><p style=\"text-align: left;\">This data further expands Keytruda&#39;s indication footprint in precision oncology. Recent positive developments including FDA approval of Keytruda plus Padcev for muscle-invasive bladder cancer and Keytruda plus Trodelvy for first-line triple-negative breast cancer, combined with multiple investment banks raising price targets — JPMorgan to $140, BMO to $142, Wells Fargo to $150, and Scotiabank to $155 — have collectively bolstered market sentiment.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1192281608","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192281608","pubTimestamp":1784120399,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"走势提醒|默沙东盘前交易涨3.49%，Keytruda 3期子宫内膜癌试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/95398b1f861a6b6846db524c0ee34ced","symbols_score_info":{"MRK":1},"content_text":"On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. The study demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.This data further expands Keytruda's indication footprint in precision oncology. Recent positive developments including FDA approval of Keytruda plus Padcev for muscle-invasive bladder cancer and Keytruda plus Trodelvy for first-line triple-negative breast cancer, combined with multiple investment banks raising price targets — JPMorgan to $140, BMO to $142, Wells Fargo to $150, and Scotiabank to $155 — have collectively bolstered market sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192281608","isCrawlerRequest":true}